Public-Private Partnerships in Drug Development for Underdeveloped Countries: An Interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division
In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler...
| Autor principal: | |
|---|---|
| Tipo de documento: | Recurso Electrónico Artigo |
| Idioma: | Inglês |
| Verificar disponibilidade: | HBZ Gateway |
| Journals Online & Print: | Carregar...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Publicado em: |
Cambridge Univ. Press
2003
|
| Em: |
Cambridge quarterly of healthcare ethics
Ano: 2003, Volume: 12, Número: 4, Páginas: 429-433 |
| Acesso em linha: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| Resumo: | In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler discusses the origins and nature of this agreement that could set a pattern for how corporations and nonprofit organizations can work together in drug development. |
|---|---|
| ISSN: | 1469-2147 |
| Obras secundárias: | Enthalten in: Cambridge quarterly of healthcare ethics
|
| Persistent identifiers: | DOI: 10.1017/S0963180103124127 |